“JDRF congratulates Vertex Pharmaceutical on the announcement of positive results from the phase I/II clinical trial for VX-880. As early funders of beta cell replacement therapies, we are excited to see continual advancement around this area of research, which can ultimately lead to a cure for the type 1 diabetes community. 

We look forward to additional results as the trial continues, and JDRF is committed to see beta cell replacement therapies in the hands of people with T1D and other insulin requiring diabetes.”

– Sanjoy Dutta, Ph.D., JDRF Vice President, Research